1.
EJHaem
; 5(1): 238-241, 2024 Feb.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38406527
RESUMEN
Central nervous system (CNS) involvement by mantle cell lymphoma (MCL) is rare and portends a poor prognosis. We describe the first patient to have a complete response with front-line treatment with single-agent acalabrutinib for MCL CNS.